Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | BRS3 | P32247 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863103 | 0.87 | SMN1; SMN2 (0.45) | PTPN11ALDH1A1RAB9A | |
| SCHEMBL5863286 | 0.86 | PTGER1 (0.47) | ALDH1A1BRS3PTGER4PTGER3PTGER1 | |
| SCHEMBL5863189 | 0.83 | NR4A2 (0.57) | ALDH1A1PTGER1NR4A2PKM | |
| SCHEMBL5863160 | 0.82 | NR4A2 (0.53) | NR4A2PKMFFAR1FFAR4 | |
| Hydrochloric Acid SCHEMBL5863297 | 0.81 | KDM4E (0.41) | ALDH1A1RAB9APKM | |
| SCHEMBL5863455 | 0.80 | MCHR1 (0.42) | ALDH1A1 | |
| SCHEMBL5864900 | 0.80 | DRD3 (0.42) | ALDH1A1 | |
| SCHEMBL5863144 | 0.79 | ALDH1A1 (0.49) | PTPN11ALDH1A1RAB9APTGER4PTGER3 | |
| SCHEMBL5863212 | 0.76 | PTGER1 (0.49) | PTPN11RAB9APTGER4PTGER3PTGER1 | |
| SCHEMBL7743316 | 0.76 | MRGPRX4 (0.60) | CYP4F2CYP4A11PTGER1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132456-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2006-11-07 | — | — | US | claimed |
| US-20060052449-A1 | Novel mch receptor antagonists | ELI LILLY AND COMPANY | 2006-03-09 | — | — | US | claimed |
| EP-1572637-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-14 | — | — | EP | claimed |
| WO-2004052848-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | claimed |
| US-7132456-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060052449-A1 | Novel mch receptor antagonists | ELI LILLY AND COMPANY | 2006-03-09 | — | — | US | disclosed |
| EP-1572637-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052848-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052449-A1 | Novel mch receptor antagonists | MCHR1, MCHR2, MC1R | CYP4F2 3158/4885CYP4A11 1583/4885PTPN11 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.